Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4651 to 4665 of 7684 results

  1. Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups would be useful.

    Recommendation ID TA236/2 Question Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups

    Research recommendation
    Published
    9 June 2015

  2. Further research into the comparative efficacy and safety of different surgical and ablative treatments would be useful.

    Recommendation ID IPG405/1 Question Further research into the comparative efficacy and safety of different surgical and ablative treatments

    Research recommendation
    Published
    9 June 2015

  3. Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral neuropathy.

    Recommendation ID MTG38/1 Question Further research is needed on the benefits and consequences of detecting preclinical diabetic peripheral

    Research recommendation
    Published
    3 January 2019

  4. In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed that further research into the treatment benefit of burosumab in young people aged 13 years and over would relieve some of the clinical uncertainty in an age group covered by the marketing authorisation.

    Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed

    Research recommendation
    Published
    22 March 2019

  5. Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when added to current practice. This includes research into optimal cut-off values for tests and the investigation of repeat testing strategies in people with intermediate levels of faecal calprotectin. Development of a consistent definition for the 'intermediate range' is encouraged.

    Recommendation ID DG11/2 Question Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when

    Research recommendation
    Published
    9 June 2015

  6. Further research is needed on the use and clinical utility of faecal calprotectin testing, and support pathways for the long-term management of these conditions in the community should be developed.

    Recommendation ID DG11/1 Question Further research is needed on the use and clinical utility of faecal calprotectin testing, and support

    Research recommendation
    Published
    9 June 2015

  7. Further research is needed to understand the effect of having the additional information provided by the adjunctive colposcopy technologies on anxiety for people having a colposcopy, when this information is shown to a person during the examination.

    Recommendation ID DG32/3 Question Further research is needed to understand the effect of having the additional information provided by

    Research recommendation
    Published
    21 November 2018

  8. Further research is recommended on alternative postpartum testing strategies that do not include cord blood typing of all babies born to rhesus-D (D) negative women.

    Recommendation ID DG25/1 Question Further research is recommended on alternative postpartum testing strategies that do not include cord

    Research recommendation
    Published
    10 February 2017

  9. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) in people whose Crohn's disease is losing response to a TNF-alpha inhibitor. This could be through a prospective study, for local audit, or for submission to a registry. (The IBD Registry is being adapted to receive data on TNF-alpha inhibitor levels and antibodies against TNF-alpha inhibitors).

    Recommendation ID DG22/2 Question Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER

    Research recommendation
    Published
    21 March 2016

  10. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) to monitor TNF-alpha-inhibitor levels and antibodies to a TNF-alpha inhibitor in people with Crohn's disease whose disease responds to treatment with TNF-alpha inhibitors. This should be evaluated using prospective studies.

    Recommendation ID DG22/3 Question Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER

    Research recommendation
    Published
    21 March 2016

  11. Further research is recommended on how using sex-specific 99th percentile thresholds affects treatment decisions and clinical outcomes for men and women.

    Recommendation ID DG40/2 Question Further research is recommended on how using sex-specific 99th percentile thresholds affects treatment

    Research recommendation
    Published
    26 October 2020

  12. Further research is recommended on patient acceptability of using virtual chromoendoscopy for real-time assessment of diminutive polyps compared with assessment using histopathology

    Recommendation ID DG28/1 Question Further research is recommended on patient acceptability of using virtual chromoendoscopy for real-time

    Research recommendation
    Published
    12 October 2018

  13. Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal Pathogen Panel, the FilmArray GI Panel and the Faecal Pathogens B assay.

    Recommendation ID DG26/1 Question Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal

    Research recommendation
    Published
    17 February 2017

  14. Further research is recommended on: The accuracy of EarlyCDT Lung, and the validity of the risk models used to combine EarlyCDT Lung results with the Brock and the Herder risk models. The impact of EarlyCDT Lung on clinical management decisions. A large retrospective audit is recommended to: Understand how patient and nodule characteristics impact on malignancy prevalence and disease progression. Understand current practice regarding clinical management of people with intermediate-risk lung nodules. Determine the clinical consequences of CT surveillance, including the likelihood of disease progression during CT surveillance. Determine the likelihood and impact of unnecessary biopsy or resection of indolent and benign nodules If existing data on these points is limited or not routinely collected, a prospective data collection should be undertaken to obtain it.

    Recommendation ID DG46/01 Question Further research is recommended on: The accuracy of EarlyCDT Lung, and the validity of the risk models

    Research recommendation
    Published
    24 March 2022

  15. Further research is recommended on the diagnostic performance of the TriageTrue high-sensitivity troponin test using samples at point of care.

    Recommendation ID DG40/1 Question Further research is recommended on the diagnostic performance of the TriageTrue high-sensitivity troponin

    Research recommendation
    Published
    26 October 2020